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ing systemic chemotherapy. Such risk models may have applicability in 
identifying patients at increased risk for early NC. Independent valida-
tion of these models will be conducted in a separate population of lung 
cancer patients.
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In 2002 a proposal was made to Macmillan Cancer Relief (now known 
as Macmillan Cancer Support) to support the establishment of Meso-
thelioma UK, the National Macmillan Mesothelioma Resource Centre 
at Glenﬁeld Hospital, Leicester. The Centre opened in 2004. 
Methods: 
The objectives of the centre are:
• To provide high quality, impartial and up-to-date information to all 
UK mesothelioma patients, their carers, health care professionals 
and associated organisations. 
• To provide regional support for ongoing development in the me-
sothelioma ﬁeld through the continued development of a national 
network of trained and experienced nurse specialists. 
• To establish a consultant nurse post to provide overall leadership to 
the work of Mesothelioma UK, including nurse-led research. 
• To work in collaboration with individuals interested in mesothe-
lioma and with interest related groups.
• To explore the feasibility of establishing and developing a network 
of mesothelioma support groups.
• To promote the problems and issues raised by mesothelioma through 
mediums such as articles, conferences and the media.
Results: From the current progress already achieved by the Macmillan 
Mesothelioma UK Project, it can be anticipated that all its objectives 
will be achieved by the end of the three years. The value of services 
provided by Mesothelioma UK on a national level, to the public and to 
health care, can already be demonstrated and is expected to grow. 
Conclusion: This presentation will chart the development of Mesothe-
lioma UK and highlight the achievements and beneﬁts of establishing 
a co-ordinated approach to provide support and information for a rare 
tumour such as mesothelioma.
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Background: The multidisciplinary provincial Lung Disease Site 
Group (LDSG) has met regularly for the past 10 years to develop 
practice guidelines (PGs). Current members include medical (17) and 
radiation (11) oncologists, thoracic surgeons (4) and research coordina-
tors (1). A medical sociologist, patients, pathologists, and nurses have 
participated in speciﬁc PG development activities.
Methods: The LDSG has used the practice guideline (PG) develop-
ment cycle described by Browman GP et al (JCO 1998; 16(3):1226-
31).
Results: 31 reports, including 25 PGs have been published in peer-
reviewed journals and all PG’s are posted on CCO’s website, www.
cancercare.on.ca. Initial guideline topics were selected on the basis of 
known practice variation, controversy in practice, or new and emerging 
data with potential to change practice. PGs for single chemotherapy 
drugs (6) or chemotherapy usage for speciﬁc situations (7) have 
dominated DSG activity and have commonly informed the provincial 
funding decisions that make new and expensive drugs available for 
speciﬁc indications.
5 PGs on radiotherapy alone and 3 on RT as part of combined modality 
therapy (CMT) have been completed. An analysis of fractions used for 
curative radiotherapy in stage III NSCLC by treatment centre suggests 
wide adoption although low numbers of treated patients per Centre 
implies that appropriate patients are either not being referred or co-
morbidities in this patient population preclude the routine application 
of PG recommendation. 
A review of evidence on Positron Emission Tomography (PET) in 
lung cancer supported its use in the assessment of solitary pulmonary 
nodules when other diagnostic tests failed, but provided conﬂicting evi-
dence in relation to its role in the clinical management of early stage, 
potentially resectable (Stage I-IIIa) and locally advanced, inoperable 
NSCLC. As a consequence, two clinical trials have been initiated to 
evaluate the clinical utility of PET in managing patients with NSCLC.
Conclusion: LDSG PGs have informed Ontario government funding 
decisions for chemotherapy drugs, inﬂuenced radiation therapy practice 
in Ontario cancer treatment centres and resulted in evaluative studies of 
PET technology. As well, through an updating process, they remain an 
excellent reference on current best practice that can be used by trainees 
and practitioners globally.
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Background: Recent data from both the National Cancer Institute of 
Canada (NCIC) and other studies has shown that early stage NSCLC 
patients receiving adjuvant chemotherapy after complete resection may 
have a signiﬁcant survival advantage as compared to surgery alone. The 
NCIC JBR10 study showed that 91% of patients receiving platinum-
based adjuvant chemotherapy experienced anemia, with 38% being 
grade 2 or higher. It is well known that platinum-based chemotherapy 
causes anemia. Subsequent exploratory analyses to this study docu-
menting the rate of anemia in the adjuvant NSCLC patient population 
and assessing impact on outcomes demonstrated that lower baseline 
